The U.S. Supreme Court on
Monday rebuffed a bid by Bristol Myers Squibb Co s Juno
Therapeutics Inc to reinstate a $1.2 billion award it won in its
patent fight with Gilead Sciences Inc subsidiary. | November 7, 2022
The US Supreme Court on Monday rebuffed a bid by Bristol Myers Squibb s Juno Therapeutics to reinstate a $1.2 billion award it won in its patent fight with Gilead Sciences subsidiary Kite Pharma over a lymphoma drug.
That is compared with 5,643 new cases a day earlier – 569 symptomatic and 5,074 asymptomatic infections, which China counts separately. Some in White House worry abortion message bungled before midterms Some senior White House officials have been second-guessing their messaging to voters around abortion in recent weeks, sources familiar with the matter said, as forecasts turned in Republicans' favor in the run up to the midterm elections.
By Blake Brittain WASHINGTON (Reuters) -The U.S. Supreme Court on Monday rebuffed a bid by Bristol Myers Squibb Co's Juno Therapeutics Inc to reinstate a $1.2 billion award it won in its patent fight with
By Blake Brittain WASHINGTON (Reuters) -The U.S. Supreme Court on Monday rebuffed a bid by Bristol Myers Squibb Co's Juno Therapeutics Inc to reinstat.